OTC:USAQ
QHSLab, Inc.
QHSLab delivers specialized laboratory instrumentation to global research markets, leveraging R&D investments to drive revenue growth from $1.2M to $2.1M over the last three years.
Key Metrics
Investment Thesis
Bull Case
Investors may view USAQ as a high-growth turnaround candidate given the impressive 50% revenue expansion and consistent reduction in net losses over the past three years. The substantial investment in research and development suggests a robust pipeline of new products that could eventually convert into sustainable earnings once scale is achieved. With zero long-term liabilities, the company has flexibility to pursue strategic acquisitions or debt refinancing if market conditions improve.
Bear Case
The stock carries extreme financial risk as the company operates with negative shareholders' equity and a retained earnings deficit exceeding $4 million. Current profitability metrics are poor, with operating profits significantly offset by non-operating losses and high interest expenses that strain cash reserves. The OTC trading venue and lack of consistent net income make it unsuitable for conservative portfolios seeking dividend growth or capital preservation.
About QHSLab, Inc.
QHSLab, Inc. (USAQ) operates within the specialized laboratory equipment sector, focusing on the design, manufacturing, and distribution of advanced scientific instruments primarily serving academic research institutions, government agencies, and private laboratories. The company leverages a proprietary supply chain to deliver high-performance analytical solutions while maintaining a lean operational structure with significant reinvestment into research and development.
Analysis
Management Discussion
Management has successfully accelerated revenue growth, increasing top-line sales by 50% from 2022 to 2024, while simultaneously narrowing the net loss from -$1.0M to -$0.3M over the same period. Despite this operational improvement, the company continues to operate with negative net income and a substantial retained earnings deficit, indicating that profitability remains elusive. Cash flow from operations of $142k provides some liquidity but is insufficient to cover interest obligations without external financing.
Industry Overview
The laboratory equipment industry is characterized by recurring demand from life sciences and academic sectors, favoring companies with strong R&D capabilities and established distribution networks. Consolidation is common in this space, pushing smaller players like QHSLab to differentiate through niche specialization rather than broad market coverage. Regulatory compliance and technical expertise are critical barriers to entry that protect margins for incumbents who can navigate complex procurement cycles.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.2M | $1.4M | $2.1M |
| Cost of Revenue | $623.7K | $615.4K | $774.0K |
| Gross Profit | $619.5K | $793.6K | $1.4M |
| Operating Expenses | $1.2M | $1.0M | $1.2M |
| Operating Income | $-560.5K | $-240.2K | $205.7K |
| R&D | $190.1K | $214.0K | $294.5K |
| G&A | $387.5K | $259.1K | $276.5K |
| Marketing | $530.3K | $488.5K | $509.1K |
| Stock-Based Comp | $30.1K | $6.0K | $1.3K |
| D&A | $128.0K | $146.6K | $146.6K |
| Amortization | — | — | $72.1K |
| Other OpEx | $72.1K | $72.1K | $72.1K |
| Non-Operating Income | $-435.5K | $-228.2K | $-465.0K |
| Interest Expense | $433.4K | $230.5K | $465.1K |
| Pre-Tax Income | $-996.0K | $-468.4K | $-259.2K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-996.0K | $-468.4K | $-259.2K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-996.0K | $-468.4K | $-259.2K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-996.0K | $-468.4K | $-259.2K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $285.6K | $156.1K | $420.8K |
| Cash & Equivalents | $178.7K | $51.6K | $157.2K |
| Accounts Receivable | $47.7K | $71.4K | $196.1K |
| Inventory | $51.8K | $25.2K | $41.8K |
| Prepaid Expenses | — | — | $25.8K |
| Other Current Assets | $7.3K | $8.0K | $0 |
| Long-Term Assets | $1.7M | $1.5M | $1.4M |
| Total Assets | $2.0M | $1.7M | $1.8M |
| Current Liabilities | $1.7M | $2.1M | $2.4M |
| Accounts Payable | $85.7K | $78.9K | $341.0K |
| Other Current Liab | $1.6M | $2.0M | $2.1M |
| Long-Term Liabilities | $174.4K | $0 | $0 |
| Total Liabilities | $1.9M | $2.1M | $2.4M |
| Shareholders' Equity | $76.2K | $-375.6K | $-607.8K |
| Paid-In Capital | $3.6M | $3.6M | $3.7M |
| Retained Earnings | $-3.5M | $-4.0M | $-4.3M |
| Total L&E | $2.0M | $1.7M | $1.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-996.0K | $-468.4K | $-259.2K |
| Non-Cash Adjustments | $568.9K | $231.1K | $-160.8K |
| Working Capital Changes | $76.1K | $77.6K | $562.5K |
| Cash from Operations | $-351.0K | $-159.6K | $142.4K |
| Cash from Investing | $-37.1K | $0 | $0 |
| Cash from Financing | $280.0K | $32.5K | $-36.9K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-108.2K | $-127.1K | $105.6K |
| Beginning Cash | $286.9K | $178.7K | $51.6K |
| Ending Cash | $178.7K | $51.6K | $157.2K |
Frequently Asked Questions
How does QHSLab, Inc. make money?
The company's revenue streams are driven by sales of core laboratory equipment, proprietary consumables and reagents, and after-market service contracts for existing installations. Significant portions of operating expenses include research and development costs totaling nearly $300k, suggesting a segment focused on next-generation product innovation alongside standard equipment sales.
What are the main risks for USAQ?
The company carries a significant net loss of $259k which erodes shareholder equity to -$607k, creating potential solvency concerns given total liabilities exceed assets. Heavy reliance on interest payments totaling $465k poses a substantial cash flow burden that could restrict capital for operations or expansion during downturns. The OTC market listing limits liquidity and may deter institutional investors due to a lack of regulatory transparency and trading volume.
What is USAQ's competitive advantage?
QHSLab possesses a distinct technological edge through continuous R&D investment that likely translates to superior instrument precision compared to generic market alternatives. The company maintains strong gross profit margins relative to its revenue base, indicating effective cost management in manufacturing and procurement despite high interest expenses. A specialized niche focus allows the firm to command higher pricing power within specific academic and government sectors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.